Buy Selank Peptide

Overview of Selank in Preclinical Research

Selank is a synthetic heptapeptide (sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the naturally occurring human immunomodulatory peptide tuftsin. Developed as a stable analog, Selank incorporates a Pro-Gly-Pro tripeptide sequence at its C-terminus, which significantly enhances its resistance to enzymatic degradation by serum peptidases compared to its parent compound.

In experimental models, researchers study Selank to investigate its potential interactions with central nervous system pathways, neuromodulation mechanisms, and metabolic stability. When institutions seek to buy Selank peptide for in vitro or animal studies, ensuring exact sequence fidelity, absence of truncated peptide impurities, and low endotoxin burdens is critical to preventing confounding experimental outcomes.

Chemical Profile and Structural Properties

Selank possesses a molecular formula of C33H57N11O9 and a molecular weight of approximately 751.9 g/mol. The incorporation of the C-terminal Pro-Gly-Pro fragment alters the secondary structure, imparting structural rigidity and shielding labile peptide bonds against endopeptidases.

The primary sequence of Selank relies on precise solid-phase peptide synthesis (SPPS) protocols to maintain correct stereochemistry across all amino acid residues. Impurities such as deletion sequences or residual protecting groups can alter receptor binding kinetics in biochemical assays. Consequently, analytical validation via reversed-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry is mandatory for every production lot.

Preclinical Mechanisms and Receptor Targets

Preclinical literature indicates that Selank interacts with multiple neurochemical systems without exhibiting direct binding affinity for classical benzodiazepine receptor sites. Instead, in vitro assays suggest that Selank modulates the allosteric sites of gamma-aminobutyric acid type A (GABA-A) receptors, influencing GABA-mediated chloride current currents.

Furthermore, rodent models demonstrate that Selank administration influences the expression of brain-derived neurotrophic factor (BDNF) and mRNA levels of neurotrophin receptors in the hippocampus. Additional in vitro findings highlight Selank's capacity to inhibit enkephalin-degrading enzymes (such as neutral endopeptidase and carboxypeptidase N), thereby prolonging the endogenous biological activity of enkephalins in neuronal tissue preparations.

In immunomodulatory studies, investigators have observed that Selank alters interleukin-6 (IL-6) expression and modulates T-helper cell cytokine balance in cellular cultures. These findings make Selank a versatile subject within the broader field of neuropeptide research.

Comparative Analysis: Selank and Related Neuropeptides

Within neurobiological investigation, Selank is frequently evaluated alongside other synthetic neuropeptides and neurotrophic modulators. A primary compound of comparison is Semax, an ACTH(4-10) analog that similarly incorporates a C-terminal Pro-Gly-Pro sequence to enhance enzymatic stability. While Semax research frequently focuses on melanocortin signaling and neurotrophic factor up-regulation, Selank investigations emphasize GABAergic modulation and enkephalinase inhibition pathways.

Researchers also study modified analogs such as N-Acetyl Selank Amidate, which features N-terminal acetylation and C-terminal amidation designed to further alter lipophilicity and metabolic half-life in physiological matrices. Additionally, non-peptide small molecules such as Dihexa are evaluated in similar neurodegeneration and synaptogenesis models, offering distinct comparative mechanisms for laboratory cross-examination.

Selecting among these compounds depends strictly on the intended experimental target—whether investigating peptidase resistance, BDNF induction pathways, or neuroimmunological responses.

Laboratory Quality Standards and Analytical Verification

The accuracy of preclinical data relies entirely on the purity of the research reagents employed. When you buy Selank peptide from PX1 Research, every batch undergoes comprehensive analytical testing conducted by independent ISO 17025 accredited laboratories.

Quality assurance verification for PX1 Research compounds includes:

• Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm peptide purity levels of 99% or greater. • Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise monoisotopic mass and sequence identity. • Chromogenic LAL Assays to measure bacterial endotoxin levels, ensuring suitability for sensitive cell cultures. • Residual Solvent Analysis to confirm the total elimination of synthesis reagents such as trifluoroacetic acid (TFA) and dimethylformamide (DMF).

Every standard lyophilized vial is paired with a lot-specific Certificate of Analysis (COA) directly accessible for audit by principal investigators and laboratory managers.

Reconstitution Guidelines for In Vitro Workflows

Selank is supplied as a sterile, lyophilized white powder inside sealed glass vials. To maintain chemical stability and concentration accuracy during experimental protocols, proper reconstitution procedures must be maintained.

1. Aseptic Preparation: Reconstitute vials inside a laminar flow hood using sterile laboratory equipment. 2. Solvent Selection: Use Bacteriostatic Water (0.9% benzyl alcohol) for multi-use laboratory reagents, or sterile 0.9% Sodium Chloride / Phosphate-Buffered Saline (PBS) for immediate cell culture applications. 3. Reconstitution Technique: Direct the solvent stream down the inner glass wall of the vial rather than directly onto the lyophilized cake. Gently swirl the vial until dissolved—do not agitate or vortex vigorously, as mechanical shear stress can denature peptide chains. 4. Aliquoting: To prevent degradation from repeated freeze-thaw cycles, aliquot the reconstituted stock solution into single-use polypropylene microcentrifuge tubes prior to storage.

Storage and Stability Recommendations

Lyophilized Selank peptide should be stored at -20°C for long-term stability, where it remains stable for up to 24 months. For short-term storage during active trial phases, desiccated lyophilized vials may be maintained at 2°C to 8°C for several weeks without significant degradation.

Once reconstituted in aqueous solution, stock aliquots must be stored at -20°C or -80°C and used within 30 to 90 days depending on the buffer chosen. Avoid exposing peptide solutions to direct ultraviolet light or ambient room temperatures for extended periods.

Institutional Procurement and Wholesale Availability

PX1 Research supports academic institutions, biotechnology firms, and contract research organizations (CROs) requiring reliable, high-volume supply chains. All compounds are manufactured within state-of-the-art facilities located in the United States.

Orders placed before standard cutoff times ship the same day from our fulfillment centers in California and Arizona. For high-throughput laboratory projects requiring bulk synthesis or custom packaging configurations, visit our wholesale portal to establish an institutional research account.